Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib and Liposomal Doxorubicin in Advanced Ovarian Cancer
NCT01035658Phase 2Terminated
- Sponsor
- SCRI Development Innovations
- Start
- Jan 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pazopanib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (4 arms), sponsored by SCRI Development Innovations. Primary endpoints: Maximum Tolerated Dose at 18 months, Dose Limiting Toxicities at 18 months and 1 more. Started Jan 2010; status: terminated.
02
Drugs
pazopanib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01035658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01035658.